In plain words
Zuranolone is a prescription medicine taken by mouth. It is approved in the United States for in adults. It works on the same brain receptors as , a hormone that changes sharply after birth. Some people notice relief within days, which is faster than many antidepressants. It can cause drowsiness and dizziness, and the label warns about driving and other activities that need full attention. Some providers prescribe it when other treatments are not enough. Ask your provider whether it fits your situation and what it would replace or add to.
The deeper version
Zuranolone is an orally active neuroactive steroid and positive allosteric modulator of receptors, approved by the FDA in August 2023 for postpartum depression in adults, following , an intravenous formulation approved in 2019. Phase 3 trials (Deligiannidis et al., 2023) reported improvement on depression scales within the first weeks, with a sedation and dizziness profile and a boxed warning for impaired ability to drive. Its mechanism is related to the withdrawal of endogenous allopregnanolone after delivery. Long-term efficacy and comparison with first-line antidepressants and psychotherapy are less established, and cost and access are active policy questions.
Where it comes up
- Postpartum depressionPostpartum: Mind
- Therapy and medication after birth: what the options arePostpartum: Mind
- Postpartum anxietyPostpartum: Mind
- When to get help, and who to call tonightPostpartum: Mind
What mothers here say about zuranolone
No one has posted under this term yet.
Sources
- US Food and Drug Administration — Zurzuvae (zuranolone) prescribing information, approved August 2023
- Deligiannidis KM et al. — Zuranolone for postpartum depression: phase 3 trial results, 2023
- American College of Obstetricians and Gynecologists — Clinical Practice Guideline No. 5: Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum, 2023